Nicholas J. Sarlis
Technik-/Wissenschafts-/F&E-Leiter bei Sellas Life Sciences Group Ltd.
Profil
Nicholas J.
Sarlis is currently the Chief Medical Officer & Senior Vice President at Sellas Life Sciences Group Ltd.
He previously worked as the Vice President & Head-Global Medical Affairs at Incyte Corp.
from 2010 to 2016.
Prior to that, he was an Associate Professor at The University of Texas M.D.
Anderson Cancer Center from 2002 to 2006 and later returned to the same institution as an Associate Professor.
He also served as the Chief Medical Officer & Executive Vice President at SELLAS Life Sciences Group, Inc. from 2017 to 2020.
Sarlis earned his doctorate from the University of London in 1992 and his undergraduate and another doctorate degree from National & Kapodistrian University of Athens in 1988 and 1989, respectively.
Aktive Positionen von Nicholas J. Sarlis
| Unternehmen | Position | Beginn |
|---|---|---|
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Nicholas J. Sarlis
| Unternehmen | Position | Ende |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2020 |
| INCYTE CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2016 |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Corporate Officer/Principal | 01.01.2006 |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Corporate Officer/Principal | - |
Ausbildung von Nicholas J. Sarlis
| University of London | Doctorate Degree |
| National & Kapodistrian University of Athens | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
